Answers are grounded in this paper and cite their sources.
Macrophage activation is central to the pathogenesis of a number of diseases that involve the excessive release of inflammatory mediators such as cytokines and nitric oxide (NO). Recent studies have shown that adenine nucleotides (ATP/ADP) and their receptors (P2 receptors, especially the P2Y class) are critically linked to macrophage responsiveness. We have found that lipopolysaccharide (LPS, endotoxin) stimulation of macrophages is modulated by purines wherein an ATP analog, 2-methylthio-ATP (2-MeS-ATP), reduces macrophage activation in both in vitro and in vivo models of endotoxemia. Specifically, the nucleotides 2-MeS-ATP and 2-Cl-ATP protect mice from a lethal challenge of LPS, and 2-MeS-ATP decreases the release of interleukin-1 (IL-1), tumor necrosis factor (TNF-α), and NO, but not IL-6 in response to LPS. Interestingly, TNF-α-stimulated NO release from macrophages is not inhibited by 2-MeS-ATP suggesting that adenine nucleotides modulate specific macrophage functions, compared with a toxic or nonselective mode of action. In this regard, it has been found that the decrease in NO release mediated by 2-MeS-ATP correlates with decreased expression of inducible nitric oxide synthase (iNOS) and iNOS mRNA in mouse peritoneal macrophages. Besides these effects on cytokine function, extracellular ATP/ADP have also been found to increase the binding of monocytes to various substrates mediated by Mac-1 integrin activation. In summary, because ATP and ADP are present in high concentrations at sites of inflammation, these purines may provide a signal for macrophage activation, and agents that modulate macrophage sensitivity to purines represent a powerful mode of therapy for a variety of inflammatory disorders such as endotoxemia. Drug Dev. Res. 39:377–387, 1996.
No takes yet. Share an insight, caveat, or question.
Fisette et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: